Lactobacillus Johnsonii in Children and Adolescents With T1D

Type 1 Diabetes (T1D) Clinical Trial

Official title:
Evaluation of the Safety, Tolerability and Immunological Response to Lactobacillus Johnsonii N6.2 in Children and Adolescents With T1D

Status Recruiting

Clinical Trial Summary

While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03961854
Study type	Interventional
Source	University of Florida
Contact	Michael Haller, MD
Phone	352-273-9264
Email	hallemj@peds.ufl.edu
Status	Recruiting
Phase	Phase 2
Start date	October 10, 2019
Completion date	May 18, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06315725` - Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients With Type 1 Diabetes (T1D)
Completed	`NCT01369082` - Extended Follow-Up After Islet Transplantation in T1D	N/A
Recruiting	`NCT03961347` - Lactobacillus Johnsonii Supplementation in Adults With T1D	Phase 2